Aberrant promoter methylation of SPARC in ovarian cancer - Wikidata - awgldk - TriplyDB

Aberrant promoter methylation of SPARC in ovarian cancer

Aberrant promoter methylation of SPARC in ovarian cancer

http://www.wikidata.org/entity/Q37073261

about

Matricellular proteins: a sticky affair with cancers Dinosaurs and ancient civilizations: reflections on the treatment of cancer SPARC Promotes Cell Invasion In Vivo by Decreasing Type IV Collagen Levels in the Basement Membrane Loss of SPARC in bladder cancer enhances carcinogenesis and progression.The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite.Hypermethylation and post-transcriptional regulation of DNA methyltransferases in the ovarian carcinomas of the laying hen.The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer.Epigenomics and ovarian carcinoma.The interconnectedness of cancer cell signaling.Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma.Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.SPARC expression and prognostic value in non-small cell lung cancer.Minireview: epigenetic changes in ovarian cancer.The War on Cancer rages on.Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance SPARC: a matricellular regulator of tumorigenesis.Roles of SPARC in urothelial carcinogenesis, progression and metastasis.Role of epigenomics in ovarian and endometrial cancers.Stromal expression of SPARC in pancreatic adenocarcinoma.Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.Epigenetic basis of cancer health disparities: Looking beyond genetic differences.Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Matricellular protein SPARC/osteonectin expression is regulated by DNA methylation in its core promoter region.Associations of tumor suppressor SPARCL1 with cancer progression and prognosis Racial health disparities in ovarian cancer: not just black and white.Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma.Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.The relationship between stromal cell derived SPARC in human gastric cancer tissue and its clinicopathologic significance.Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals.Comparative analysis of DNA methylation patterns of equine sarcoid and healthy skin samples.Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer.

P2860

Q21296660-0633ABEA-0B15-480B-B747-130857EF2233 Q24628746-F82F4CDF-777C-4DB6-9FCF-C79C97D2D9A9 Q27309073-938A2C43-0C08-4797-A557-DDC82EC6DA5F Q30422650-C00B13E8-9B7C-424D-B9AC-92FF5BC2AEF1 Q30448744-73BBA176-2E45-40E4-9865-1DC9B0FF44D4 Q33621141-92BB9BC2-1AD6-4277-B850-954B8BDA964A Q33728922-5C37FD22-08BB-483F-AB1A-7FE55835F603 Q33820209-2E131471-7787-4514-B0DC-0C1548DB7804 Q34208905-9BD4452B-68E1-4716-BA21-C62921F48868 Q34684754-FCB28117-EC58-4354-B822-86AF8F891026 Q34717933-DC0A4A8D-8B39-48A5-BE25-6BE58969A391 Q34719794-E777ADAD-B79D-4EF9-85AB-6A2C1B3F0AFA Q35636575-4A2B697E-4138-453D-B9EA-8DA3E7D96BD2 Q35669733-D247FFB6-015A-4C0F-943B-22B39B85396E Q35929159-DCC5EC33-10BA-4B14-9455-E6C4336F84CB Q36120937-6BA46D1F-F828-4BCA-977D-A0BB496BF13E Q36213561-EA78913F-7605-45E4-8CF3-39F767A1B950 Q36460449-031E3DBF-3F45-4B2D-904F-2F38CD6604B0 Q37183762-DDBF8654-636E-4375-B119-AAA9C4B62EC9 Q37328836-EB45E3A3-2D18-4418-A471-6729DBE28C5C Q37478602-CC390812-C1E5-497E-A679-1AAC0D9312F9 Q37478653-DF86A25A-42F7-4B1C-AEFE-A3CD16DB7948 Q37610020-5DB63153-92C2-40E2-A3DF-C226FB9BD164 Q37687199-FB5B2BF7-10B3-49E7-AEB2-9BD3F1F33D90 Q37961734-DDB1DDEF-D0CB-4236-B8E9-25E567C4FE28 Q38108253-04CCFB96-D80E-4A26-9225-ECDC0845FDEA Q38857783-5370C440-CAF0-4576-8BF8-CD9F4B46896A Q39096966-4ECAA70B-C11A-4C5D-AB54-A3DDEBEEDBBE Q40927491-DF79DAAE-522E-4F56-A389-1FB474BE7A6A Q41006936-6D2656D4-95B9-42D7-9BC3-D6545F364C7A Q41329235-3BA330BC-F3DE-4D0E-B27A-D437F72DB15E Q41613171-82B71292-D049-4579-AAE2-535BCAB206A0 Q41696304-6D4703AC-0BFC-4C20-8260-17F671F3483F Q41751900-61200DC8-34AE-40CF-9EA3-0EFB577A62DA Q44044551-2DA0D275-0D32-453C-B2F5-F3EECDAEA3AC Q47165057-65789408-7521-4761-8FB3-CAE374623DA3 Q47712879-EA5E7AB9-63E1-489D-819A-F0E4E2A34B53 Q48215153-69AC2FCD-CEA1-4C6D-88E8-790CE1FB373C Q51413061-FCF6626C-8667-460B-8C44-4814FA69516B Q51925660-6D13E4A0-FD85-41B2-BF6C-AEC22838627D

P2860

Aberrant promoter methylation of SPARC in ovarian cancer

http://www.wikidata.org/entity/Q37073261

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aberrant promoter methylation of SPARC in ovarian cancer

@en

Aberrant promoter methylation of SPARC in ovarian cancer.

@nl

type

label

Aberrant promoter methylation of SPARC in ovarian cancer

@en

Aberrant promoter methylation of SPARC in ovarian cancer.

@nl

prefLabel

Aberrant promoter methylation of SPARC in ovarian cancer

@en

Aberrant promoter methylation of SPARC in ovarian cancer.

@nl

P1433

Q37073261-7CA95F62-9629-465B-B967-48FB3F382F71

P1476

Q37073261-EA946056-4432-4924-BA55-D8F01155B98F

P2093

Q37073261-00C7C735-C3CE-4E9B-8C0B-6C68E8A8547F

Q37073261-191E47A3-E2D2-4093-8A16-ADD13F9A8188

Q37073261-6796631B-BC4F-472A-B80C-98B81DF7BEAA

Q37073261-72CEEAB6-86E3-4CBD-8512-58FAD0388C72

Q37073261-A563710E-8F38-4F50-BD96-A5E0ECF3F341

Q37073261-DCD86733-2D26-40D9-A43A-F32F1F775C99

Q37073261-E7A9B1E3-6164-4ED9-8173-9288C6648F09

P2860

Q37073261-009E1CA9-48AD-4FED-A9F9-082AEC7B0737

Q37073261-0FB306E4-4778-4153-8FDC-D14E6B46EFBF

Q37073261-11601442-36DA-4FE3-A392-2FB6132427C3

Q37073261-119A0BD8-4FEB-456E-8B68-9A2D83CDC1B2

Q37073261-21998DA2-36D5-4C37-8F9E-5352D603DD3C

Q37073261-2628ABFF-483F-4DAF-B9A5-E2E354E42C1A

Q37073261-30058383-F2A2-4A87-B481-DF8F22F878AF

Q37073261-3013D4FF-F854-4EA1-A5B1-D417E08920A3

Q37073261-321B6125-4C8E-42CD-B751-DEDD3863B46D

Q37073261-3E98B8C6-D164-433F-ACC5-EB3C999DE7B3

P304

Q37073261-99170689-B31B-4B1B-AF42-AB87C9B7F513

P31

Q37073261-61E10AA5-7290-4F57-A440-39FB99E73C7D

P356

Q37073261-3BE0B2E1-3B67-4BBA-8585-D71ECAD3702A

P433

Q37073261-70627AA2-AC66-4423-B5B1-EFA9FC087995

P478

Q37073261-1FE3FFE5-7F18-45DA-BEC7-9A550D86AB88

P50

Q37073261-A5F1A9CE-F100-4112-A3E2-A2E437B140AD

Q37073261-E6F4B2AD-B3F0-4D1E-873D-9D0EB8673A7B

P577

Q37073261-8F922748-2064-4645-AF4D-F5F974870D58

P5875

Q37073261-0E44C7DD-CC35-4829-B746-63DC24525668

P698

Q37073261-AE75D205-D621-4C08-BD02-1B6DC3422314

P921

Q37073261-5C2C57DD-6FF2-4008-BEA1-839ED5C12D0E

P932

Q37073261-3D55DC3E-6C56-4470-B637-6ACC8015CFBC

P356

P1433

P1476

Aberrant promoter methylation of SPARC in ovarian cancer

@en

P2093

Kouros Motamed

http://www.w3.org/2001/XMLSchema#string

Matthew J Socha

http://www.w3.org/2001/XMLSchema#string

Neil Desai

http://www.w3.org/2001/XMLSchema#string

Neveen Said

http://www.w3.org/2001/XMLSchema#string

Preetha Ramalingam

http://www.w3.org/2001/XMLSchema#string

Samuel C Mok

http://www.w3.org/2001/XMLSchema#string

Vuong Trieu

http://www.w3.org/2001/XMLSchema#string

P2860

The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

The biology of SPARC, a protein that modulates cell-matrix interactions

SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer.

DNA methylation and chromatin modification.

SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells.

SPARC, a matricellular protein: at the crossroads of cell-matrix.

SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury

P304

126-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.81146

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23957381

http://www.w3.org/2001/XMLSchema#string

P698

19177197

http://www.w3.org/2001/XMLSchema#string

P921

P932

2631137

http://www.w3.org/2001/XMLSchema#string